Enhanced Translation Of Epstein-Barr Virus Nuclear Protein, EBNA1, As A Target Fot T Cell-based Immunotherapy
Funder
National Health and Medical Research Council
Funding Amount
$380,558.00
Summary
Epstein-Barr virus, (EBV) is a human herpesvirus associated with a range of human cancers. EBNA1, an important EBV antigen, was thought to be “immunologically silent” however, recent studies from our laboratory show that EBNA1 is recognized by our body's defence system and these observations raise the possibility that EBNA1 may be an exploitable, immuno-therapy target for treating EBV-associated cancers.
Competition For Polarity Influences Lymphocyte Differentiation And Function
Funder
National Health and Medical Research Council
Funding Amount
$380,558.00
Summary
CD46 is a protein on human cells that viruses and bacteria bind to during infection. Our laboratory has found that binding of CD46 on immune cells impairs their ability to recognize and kill target cells and may explain the immunosuppression caused by measles infection. We aim to investigate the mechanisms behind the effect of CD46 on immune cells. The outcomes of this study will define new paradigms in lymphocyte biology and determine how CD46 influences the immune response to infection.
Understanding Natural Killer Cell Development And Target Recognition
Funder
National Health and Medical Research Council
Funding Amount
$408,388.00
Summary
Immune detection and eradication or control of cancer and cancer immunotherapies are based in part on the idea that tumour-specific white blood cells can protect the body from tumour development, growth and metastases. While strong evidence supports this, the means by which these white cells first recognize the cancerous tissue is largely unknown. We will study a new family of white blood cell receptors that may be important in this recognition, either naturally or following therapy.
The Role Of Glycans In Arboviral Disease; From Immunomodulation To Glycotherapeutic Treatment Strategies
Funder
National Health and Medical Research Council
Funding Amount
$419,180.00
Summary
Dengue and chikungunya viruses are leading causes of emerging mosquito-transmitted (arboviral) disease worldwide. Currently there are no available vaccines or therapeutics making combatting these arboviral diseases one of our most pressing global health challenges. Preliminary evidence shows that glycan recognition is critical for disease immunopathogenesis. This project focuses on the role of viral glycans in arboviral disease with the aim of identifying and expanding on new therapeutic targets
Host-pathogen Interaction: The Battle For Supremacy
Funder
National Health and Medical Research Council
Funding Amount
$480,014.00
Summary
This grant will provide salary support for Dr Rowena Bull. Dr Bull's research is focused on understanding the disease process between the human host and the infecting virus. The outcomes of this research will be used to find novel ways to fight viral infections with vaccines and drugs.
Systems Immunology Of Antigen Specific T Cells: From Single-cell To Immune Protection
Funder
National Health and Medical Research Council
Funding Amount
$470,144.00
Summary
T cells are key for establishment of immune protection and object of ongoing research in vaccines and more recently immunotherapy against infections and some cancers. Their dynamics are complex and many mechanisms remain unknown that could be exploited for modern therapies. Here, in a systems approach I will combined single cell technologies, immunology and computational biology to identify the factors that determine the establishment of long term memory cells utilising a unique set of samples.